New 17P data somewhat disappointing



17-alpha hydroxyprogesterone (17P) may reduce preterm deliveries, but it doesn't seem to reduce perinatal deaths. At least that's the conclusion of a large study reported at this year's Annual Clinical Meeting. To reach that conclusion, University of Miami investigators examined a database of high-risk patients with prior preterm deliveries (PTD) (n=699) and current singleton gestations who had been receiving weekly 250 mg IM injections of 17P, or observation (n=880). While those on progesterone delivered at 36.2 weeks (+/- 4.2), compared to 35.5 weeks ( +/- 4.2) (P<0.001), there were no significant differences between the groups when researchers looked at the incidence of stillbirths, neonatal deaths, miscarriages at less than 24 weeks, or total perinatal deaths.

Gonzalez-Quentero VH, Smarkusky L, Carter J, et al. 17-alpha-hydroxyprogesterone caproate: perinatal mortality and pregnancy outcomes. Obstet Gynecol. 2007;109(suppl):7S.

Recent Videos
The significance of the Supreme Court upholding mifepristone access | Image Credit:
One year out: Fezolinetant displays patient satisfaction for managing hot flashes | Image Credit:
Addressing maternal health inequities: Insights from CDC's Wanda Barfield | Image Credit:
Addressing racial and ethnic disparities in brachial plexus birth Injury | Image Credit:
Innovations in prenatal care: Insights from ACOG 2024 | Image Credit:
Unlocking therapeutic strategies for menopausal cognitive decline | Image Credit:
Navigating menopause care: Expert insights from ACOG 2024 | Image Credit:
raanan meyer, md
© 2024 MJH Life Sciences

All rights reserved.